A Combination of Intrathecal and Intramuscular Application of Human Mesenchymal Stem Cells Partly Reduces the Activation of Necroptosis in the Spinal Cord of SOD1G93A Rats

Rehorova, Monika; Vargova, Ingrid; Forostyak, Serhiy; Vacková, Irena; Turnovcová, Karolína; Skalníková, Helena Kupcová; Vodička, Petr; Kubinová, Šárka; Syková, Eva; Jendelová, Pavla

doi:10.1002/sctm.18-0223

Cited by 37 publications

(31 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although Intramuscular injections of hUCB-MSCs have no effect on survival of motor neurons in the spinal cord of SOD1 transgenic mice (Supplement Fig. S5) like previous study 21 , we could find that hUCB-MSCs have protective effect on skeletal muscle of transgenic mice 25,30,31 . However, the protective mechanisms of hUCB-MSCs in skeletal muscle of ALS disease models are largely unknown.…”

Section: Discussionsupporting

confidence: 45%

“…In particular, in ALS, mesenchymal stem cells have also been used as therapeutic agents to ameliorate disease progression 20 . To date, many studies have shown that mesenchymal stem cells administered into the central nervous system, skeletal muscles or both exert positive effects on lifespan and motor function in disease models 5,7,21 . Although Intramuscular injections of hUCB-MSCs have no effect on survival of motor neurons in the spinal cord of SOD1 transgenic mice (Supplement Fig.…”

Section: Discussionmentioning

confidence: 99%

“…In this study, we performed repeated intramuscular transplantation of hUCB-MSCs in hSOD1-G 93 A mice. In a previous study, hMSC application through intramuscular injection was found to elicit positive results in hSOD1-G 93 A mice 20,21 , but how intramuscular transplantation of hUCB-MSCs improves the progression of disease is unknown. Therefore, we investigated the therapeutic mechanisms of hUCB-MSCs with regard to modulation of muscle atrophy and AMPK activation in the C2C12 myotube and skeletal muscles of hSOD1-G 93 A mice.…”

mentioning

confidence: 98%

“…Although many previous studies have investigated therapeutic agents for ALS, a successful treatment for ALS has not been found. However, stem cell therapy, which uses cells that characteristically release different growth and trophic factors that are crucial for the survival of damaged tissue and cells, is a promising option for the treatment of neurodegenerative disease 20,21 . In particular, in recent clinical trials, intrathecal and intramuscular administration of human mesenchymal stem cells (hMSCs) in patients with ALS were found to be safe and to provide beneficial effects for patients, including up to 25% improvement in the slope of progression.…”

mentioning

confidence: 99%

“…In particular, in recent clinical trials, intrathecal and intramuscular administration of human mesenchymal stem cells (hMSCs) in patients with ALS were found to be safe and to provide beneficial effects for patients, including up to 25% improvement in the slope of progression. Furthermore, another study showed that repeated intrathecal administration of MSCs showed a possible clinical effect for at least 6 months in ALS patients 7,[20][21][22][23] . Therefore, application of hMSCs could lead to the generation of beneficial effects for neurodegenerative diseases.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Repeated intramuscular transplantations of hUCB-MSCs improves motor function and survival in the SOD1 G93A mice through activation of AMPK

Kook

Lee

Shin

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is characterized by loss of motor neurons and degeneration of neuromuscular junctions. to improve disease progression, previous studies have suggested many options that have shown beneficial effects in diseases, especially stem cell therapy. in this study, we used repeated intramuscular transplantation of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and observed positive effects on muscle atrophy and oxidative stress. in an in vivo study, motor function, body weight and survival rate were assessed, and skeletal muscle tissues were analyzed by western blotting and immunohistochemistry. After intramuscular transplantation, the hUcB-MScs survived within the skeletal muscle for at least 1 week. Transplantation ameliorated muscle atrophy and the rate of neuromuscular degeneration in skeletal muscle through reductions in intracellular RoS levels. Both expression of skeletal muscle atrophy markers, muscle atrophy F-box (MAFbx)/atrogin1 and muscle RING finger 1 (MuRF1), were also reduced; however, the reductions were not significant. Moreover, transplantation of hUCB-MSCs improved protein synthesis and inhibited the inoS/no signaling pathway through AMpK activation. our results suggest that repeated intramuscular transplantation of hUcB-MScs can be a practical option for stem cell therapy for ALS.

show abstract

Section: Discussionsupporting

confidence: 45%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 98%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Repeated intramuscular transplantations of hUCB-MSCs improves motor function and survival in the SOD1 G93A mice through activation of AMPK

Kook

Lee

Shin

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

Inorganic nanoparticle‐integrated mesenchymal stem cells: A potential biological agent for multifaceted applications

Zheng,

Jiang,

et al. 2023

MedComm

View full text Add to dashboard Cite

Mesenchymal stem cell (MSC)‐based therapies are flourishing. MSCs could be used as potential therapeutic agents for regenerative medicine due to their own repair function. Meanwhile, the natural predisposition toward inflammation or injury sites makes them promising carriers for targeted drug delivery. Inorganic nanoparticles (INPs) are greatly favored for their unique properties and potential applications in biomedical fields. Current research has integrated INPs with MSCs to enhance their regenerative or antitumor functions. This model also allows the in vivo fate tracking of MSCs in multiple imaging modalities, as many INPs are also excellent contrast agents. Thus, INP‐integrated MSCs would be a multifunctional biologic agent with great potential. In this review, the current roles performed by the integration of INPs with MSCs, including (i) enhancing their repair and regeneration capacity via the improvement of migration, survival, paracrine, or differentiation properties, (ii) empowering tumor‐killing ability through agent loaded or hyperthermia, and (iii) conferring traceability are summarized. An introduction of INP‐integrated MSCs for simultaneous treatment and tracking is also included. The promising applications of INP‐integrated MSCs in future treatments are emphasized and the challenges to their clinical translation are discussed.

show abstract

Intranasal delivery of stem cells labeled by nanoparticles in neurodegenerative disorders: Challenges and opportunities

Alizadeh

Asghari

Taghizadeh‐Hesary

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Neurodegenerative disorders occur through progressive loss of function or structure of neurons, with loss of sensation and cognition values. The lack of successful therapeutic approaches to solve neurologic disorders causes physical disability and paralysis and has a significant socioeconomic impact on patients. In recent years, nanocarriers and stem cells have attracted tremendous attention as a reliable approach to treating neurodegenerative disorders. In this regard, nanoparticle‐based labeling combined with imaging technologies has enabled researchers to survey transplanted stem cells and fully understand their fate by monitoring their survival, migration, and differentiation. For the practical implementation of stem cell therapies in the clinical setting, it is necessary to accurately label and follow stem cells after administration. Several approaches to labeling and tracking stem cells using nanotechnology have been proposed as potential treatment strategies for neurological diseases. Considering the limitations of intravenous or direct stem cell administration, intranasal delivery of nanoparticle‐labeled stem cells in neurological disorders is a new method of delivering stem cells to the central nervous system (CNS). This review describes the challenges and limitations of stem cell‐based nanotechnology methods for labeling/tracking, intranasal delivery of cells, and cell fate regulation as theragnostic labeling.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

show abstract

A Combination of Intrathecal and Intramuscular Application of Human Mesenchymal Stem Cells Partly Reduces the Activation of Necroptosis in the Spinal Cord of SOD1G93A Rats

Cited by 37 publications

References 54 publications

Repeated intramuscular transplantations of hUCB-MSCs improves motor function and survival in the SOD1 G93A mice through activation of AMPK

Repeated intramuscular transplantations of hUCB-MSCs improves motor function and survival in the SOD1 G93A mice through activation of AMPK

Inorganic nanoparticle‐integrated mesenchymal stem cells: A potential biological agent for multifaceted applications

Intranasal delivery of stem cells labeled by nanoparticles in neurodegenerative disorders: Challenges and opportunities

Contact Info

Product

Resources

About